$1.763m in trade and other payables - current liabilities
And nearly $6m in non current - due in greater than 12 months etc imo This could easily halve in price after next CR like imo has occurred before and is common with most biotechs while they wait years for results etc
Look at last few CR’s prices for research etc
so research is a wonderful thing you can assess performance over time - performance of companies and of commentators - you can see if they get it right or if they are a little bent and twisted and therefore can’t call it due to their own internal bias’s
1). Q you said it could easily halve in price on CR when we were at 37 cents
we raised a small CR at 40 cents and a couple weeks later it’s not halved as you predicted it’s almost doubled... to .73 cents.
2). On Nox you were buying all you could at mid forties as they had funding in place - not very good funding - but your point was it would now rise as they had funding regardless the quality it was enough - they are now trading at .34 cents
so it would seem ‘newbies’ research should be performed on the company and the commentator.
isnt it time to stop posting and maybe go through a period of learning... a new approach may benefit you financially.
Beware - now is not the time to sell its the time to buy - period.
KZA Price at posting:
73.0¢ Sentiment: Buy Disclosure: Held
